{"entity":{"type":"insider","cik":"0001939329","url":"/insider/0001939329","json_url":"/insider/0001939329.json","name":"Averill Master Fund, Ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":51,"n_filings":10,"first":"2024-11-21","last":"2026-08-21","span_basis":"filed_date"},"name_variants":[{"name":"Averill Master Fund, Ltd.","source":"filing","n_filings":10,"first_seen":"2024-11-21","last_seen":"2026-08-21"}],"transactions":[{"id":9299835,"accession":"0000899140-26-000947","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899140-26-000947","line_url":"/filing/0000899140-26-000947","is_derivative":false,"issuer_cik":"0001827635","issuer_name":"Veradermics, Inc","issuer_ticker":"MANE","issuer_name_source":null,"issuer_url":"/issuer/0001827635","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; MONTANOVA CAPITAL, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.00001 per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750000.0,"shares_display":"750,000","price_per_share":107.25,"price_display":"107.25","price_state":"stated","total_value":80437500.0,"total_display":"80,437,500.00","total_whole":"80,437,500","shares_owned_after":2957937.0,"shares_owned_after_display":"2,957,937","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-08-19","filed_date":"2026-08-21","scope":"insider","n_lines":2},{"id":5768209,"accession":"0000899140-26-000140","txn_seq":19,"anchor":"line-19","filing_url":"/filing/0000899140-26-000140","line_url":"/filing/0000899140-26-000140","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Veradermics, Inc","issuer_ticker":"MANE","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30521.0,"shares_display":"30,521","price_per_share":36.337485993250546,"price_display":"36.34","price_state":"stated","total_value":1109056.41,"total_display":"1,109,056.41","total_whole":"1,109,056","shares_owned_after":520453.0,"shares_owned_after_display":"520,453","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-06","filed_date":"2026-02-09","scope":"insider","n_lines":2},{"id":5768207,"accession":"0000899140-26-000140","txn_seq":17,"anchor":"line-17","filing_url":"/filing/0000899140-26-000140","line_url":"/filing/0000899140-26-000140","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Veradermics, Inc","issuer_ticker":"MANE","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":96200.0,"shares_display":"96,200","price_per_share":37.99458305613306,"price_display":"37.99","price_state":"stated","total_value":3655078.89,"total_display":"3,655,078.89","total_whole":"3,655,079","shares_owned_after":455534.0,"shares_owned_after_display":"455,534","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-05","filed_date":"2026-02-09","scope":"insider","n_lines":5},{"id":5768202,"accession":"0000899140-26-000140","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000899140-26-000140","line_url":"/filing/0000899140-26-000140","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Veradermics, Inc","issuer_ticker":"MANE","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.00001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":155953.0,"shares_display":"155,953","price_per_share":37.05181888132963,"price_display":"37.05","price_state":"stated","total_value":5778342.31,"total_display":"5,778,342.31","total_whole":"5,778,342","shares_owned_after":3604141.0,"shares_owned_after_display":"3,604,141","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-02-04","filed_date":"2026-02-09","scope":"insider","n_lines":12},{"id":4090825,"accession":"0000899140-25-001479","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899140-25-001479","line_url":"/filing/0000899140-25-001479","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":77387.0,"shares_display":"77,387","price_per_share":13.44,"price_display":"13.44","price_state":"stated","total_value":1040081.28,"total_display":"1,040,081.28","total_whole":"1,040,081","shares_owned_after":9700195.0,"shares_owned_after_display":"9,700,195","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-29","filed_date":"2025-12-29","scope":"insider","n_lines":2},{"id":4090819,"accession":"0000899140-25-001479","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899140-25-001479","line_url":"/filing/0000899140-25-001479","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16836.0,"shares_display":"16,836","price_per_share":13.1,"price_display":"13.10","price_state":"stated","total_value":220551.6,"total_display":"220,551.60","total_whole":"220,552","shares_owned_after":9634395.0,"shares_owned_after_display":"9,634,395","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-26","filed_date":"2025-12-29","scope":"insider","n_lines":2},{"id":4090812,"accession":"0000899140-25-001479","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-25-001479","line_url":"/filing/0000899140-25-001479","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":50000.0,"shares_display":"50,000","price_per_share":12.85,"price_display":"12.85","price_state":"stated","total_value":642500.0,"total_display":"642,500.00","total_whole":"642,500","shares_owned_after":9620075.0,"shares_owned_after_display":"9,620,075","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-23","filed_date":"2025-12-29","scope":"insider","n_lines":2},{"id":4126726,"accession":"0000899140-25-001459","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899140-25-001459","line_url":"/filing/0000899140-25-001459","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19542.0,"shares_display":"19,542","price_per_share":12.08,"price_display":"12.08","price_state":"stated","total_value":236067.36,"total_display":"236,067.36","total_whole":"236,067","shares_owned_after":9577475.0,"shares_owned_after_display":"9,577,475","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-22","filed_date":"2025-12-22","scope":"insider","n_lines":2},{"id":4126714,"accession":"0000899140-25-001459","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899140-25-001459","line_url":"/filing/0000899140-25-001459","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16384.0,"shares_display":"16,384","price_per_share":11.48,"price_display":"11.48","price_state":"stated","total_value":188088.32,"total_display":"188,088.32","total_whole":"188,088","shares_owned_after":9560825.0,"shares_owned_after_display":"9,560,825","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-19","filed_date":"2025-12-22","scope":"insider","n_lines":2},{"id":4126702,"accession":"0000899140-25-001459","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-25-001459","line_url":"/filing/0000899140-25-001459","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10215.0,"shares_display":"10,215","price_per_share":11.24,"price_display":"11.24","price_state":"stated","total_value":114816.6,"total_display":"114,816.60","total_whole":"114,817","shares_owned_after":9546875.0,"shares_owned_after_display":"9,546,875","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-18","filed_date":"2025-12-22","scope":"insider","n_lines":2},{"id":4573617,"accession":"0000899140-25-001256","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-25-001256","line_url":"/filing/0000899140-25-001256","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1481481.0,"shares_display":"1,481,481","price_per_share":13.5,"price_display":"13.50","price_state":"stated","total_value":19999993.5,"total_display":"19,999,993.50","total_whole":"19,999,994","shares_owned_after":1819812.0,"shares_owned_after_display":"1,819,812","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-11-07","filed_date":"2025-11-10","scope":"insider","n_lines":2},{"id":4612342,"accession":"0000899140-25-000486","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899140-25-000486","line_url":"/filing/0000899140-25-000486","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":16497.0,"shares_display":"16,497","price_per_share":12.834820876523004,"price_display":"12.83","price_state":"stated","total_value":211736.04,"total_display":"211,736.04","total_whole":"211,736","shares_owned_after":8802748.0,"shares_owned_after_display":"8,802,748","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-31","filed_date":"2025-04-02","scope":"insider","n_lines":4},{"id":4090774,"accession":"0000899140-25-000479","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-25-000479","line_url":"/filing/0000899140-25-000479","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":900000.0,"shares_display":"900,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":11700000.0,"total_display":"11,700,000.00","total_whole":"11,700,000","shares_owned_after":8793245.0,"shares_owned_after_display":"8,793,245","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-26","filed_date":"2025-03-28","scope":"insider","n_lines":2},{"id":2170449,"accession":"0000899140-24-001385","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899140-24-001385","line_url":"/filing/0000899140-24-001385","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20018.0,"shares_display":"20,018","price_per_share":11.25,"price_display":"11.25","price_state":"stated","total_value":225202.5,"total_display":"225,202.50","total_whole":"225,203","shares_owned_after":7999455.0,"shares_owned_after_display":"7,999,455","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-24","filed_date":"2024-12-26","scope":"insider","n_lines":2},{"id":2170444,"accession":"0000899140-24-001385","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-24-001385","line_url":"/filing/0000899140-24-001385","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27502.0,"shares_display":"27,502","price_per_share":10.98,"price_display":"10.98","price_state":"stated","total_value":301971.96,"total_display":"301,971.96","total_whole":"301,972","shares_owned_after":7981725.0,"shares_owned_after_display":"7,981,725","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-23","filed_date":"2024-12-26","scope":"insider","n_lines":2},{"id":2299905,"accession":"0000899140-24-001318","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-24-001318","line_url":"/filing/0000899140-24-001318","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":42000.0,"shares_display":"42,000","price_per_share":9.6,"price_display":"9.60","price_state":"stated","total_value":403200.0,"total_display":"403,200.00","total_whole":"403,200","shares_owned_after":7957365.0,"shares_owned_after_display":"7,957,365","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-12-03","filed_date":"2024-12-05","scope":"insider","n_lines":2},{"id":2816686,"accession":"0000899140-24-001299","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899140-24-001299","line_url":"/filing/0000899140-24-001299","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27436.0,"shares_display":"27,436","price_per_share":10.22,"price_display":"10.22","price_state":"stated","total_value":280395.92,"total_display":"280,395.92","total_whole":"280,396","shares_owned_after":7920175.0,"shares_owned_after_display":"7,920,175","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-20","filed_date":"2024-11-21","scope":"insider","n_lines":2},{"id":2816674,"accession":"0000899140-24-001299","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899140-24-001299","line_url":"/filing/0000899140-24-001299#line-2","is_derivative":false,"issuer_cik":"0001569064","issuer_name":"Benitec Biopharma Inc.","issuer_ticker":"BNTC","issuer_name_source":null,"issuer_url":"/issuer/0001569064","owner_cik":null,"owner_name":"Averill Madison Master Fund, Ltd.; Averill Master Fund, Ltd.; Cowen Aaron; SUVRETTA CAPITAL MANAGEMENT, LLC","owner_display_name":"Averill Madison Master Fund, Ltd.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12430.0,"shares_display":"12,430","price_per_share":9.73,"price_display":"9.73","price_state":"stated","total_value":120943.9,"total_display":"120,943.90","total_whole":"120,944","shares_owned_after":7895815.0,"shares_owned_after_display":"7,895,815","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-11-19","filed_date":"2024-11-21","scope":"insider"}],"collapsed":true,"next_cursor":"2024-11-19|2816674","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001827635","name":"Veradermics, Inc","url":"/issuer/0001827635","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2026-02-09","last_seen":"2026-08-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001808898","name":"Benitec Biopharma Inc.","url":"/issuer/0001808898","role":"Director, Ten percent owner","n_filings":8,"first_seen":"2024-11-21","last_seen":"2025-12-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001939329","retrieved_at":"2026-08-24T13:15:24+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}